TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33239393

Group type: EXPERIMENTAL
Intervention: Single-cell transcriptomics from dissociated kidneys
Number of subjects: 0
Study: 33239407

Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score (PRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family history
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family history and PRS combined
Number of subjects: 0
Study: 33239440

Group type: COMPARATOR
Intervention: miR-34a-5p
Number of subjects: 22

Group type: COMPARATOR
Intervention: miR-345-5p
Number of subjects: 22

Group type: COMPARATOR
Intervention: miR-200c-3p
Number of subjects: 22

Group type: COMPARATOR
Intervention: miR-10a-3p
Number of subjects: 22
Study: 33239737

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPS ≥ 50
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPS
Number of subjects: 0
Study: 33239818

Group type: EXPERIMENTAL
Intervention: Device-measured sedentary behavior (SB) duration
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Different intensities of physical activity (PA)
Number of subjects: 144
Study: 33239899

Group type: EXPERIMENTAL
Intervention: Insulin resistance defined by Homeostatic Model Assessment for insulin-resistance cut-offs that accommodated pubertal and gender differences.
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Anthropometric, metabolic, intake-related variables, and 55 single nucleotide polymorphisms related to NAFLD and choline metabolism were evaluated.
Number of subjects: 153
Study: 33240077

Group type: EXPERIMENTAL
Intervention: Wearable sensory prosthesis (Walkasins)
Number of subjects: 45
Study: 33240091

Group type: EXPERIMENTAL
Intervention: Drug repurposing for COVID-19
Number of subjects: 16000000

Group type: EXPERIMENTAL
Intervention: Existing drugs proposed for repurposing
Number of subjects: 16000000

Group type: EXPERIMENTAL
Intervention: Regulatory and pharmacological aspects of drug repurposing
Number of subjects: 16000000
Study: 33240101

Group type: EXPERIMENTAL
Intervention: Augmented oscillations in QT variability (QTV)
Number of subjects: 895
Study: 33240121

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) as an add-on treatment to Cognitive-Behavior Therapy (CBT)
Number of subjects: 0
Study: 33240125

Group type: EXPERIMENTAL
Intervention: Physical-exercise program
Number of subjects: 0
Study: 33240196

Group type: EXPERIMENTAL
Intervention: Combining Compensatory Cognitive Training and Vocational Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 0
Study: 33240205

Group type: EXPERIMENTAL
Intervention: Upper-extremity rehabilitation using smart glove
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33240257

Group type: EXPERIMENTAL
Intervention: Western Equine Encephalitis Vaccine (WEEV; WEE TSI-GSD 210)
Number of subjects: 876
Study: 33240282

Group type: EXPERIMENTAL
Intervention: IO103 vaccine with Montanide ISA 51 adjuvant, administered subcutaneously up to fifteen times during 1 year.
Number of subjects: 10
Study: 33240315

Group type: EXPERIMENTAL
Intervention: 15-min extra counseling about prenatal screening and diagnosis
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no extra counseling)
Number of subjects: 150
Study: 33240399

Group type: EXPERIMENTAL
Intervention: Irinotecan combined with oxaliplatin and S-1
Number of subjects: 41
Study: 33240830

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33240920

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33240993

Group type: EXPERIMENTAL
Intervention: EUS-placed titanium clips
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional GTVs
Number of subjects: 55
Study: 33241512

Group type: EXPERIMENTAL
Intervention: Brock model 2b
Number of subjects: 4578

Group type: EXPERIMENTAL
Intervention: Lung-RADS
Number of subjects: 4578

Group type: EXPERIMENTAL
Intervention: Brock model 2a
Number of subjects: 4578
Study: 33242013

Group type: EXPERIMENTAL
Intervention: Soldiers (military population)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Civilians (control group)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Officers (military subgroup)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Noncommissioned Officers (NCOs) (military subgroup)
Number of subjects: 566
Study: 33242065

Group type: EXPERIMENTAL
Intervention: PAR2 antibody (MEDI0618)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZ8838 and AZ3451 (non-peptide small molecule antagonists)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAR2 antibody (Fab3949)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZ8838
Number of subjects: 0
Study: 33242441

Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transplantation
Number of subjects: 0
Study: 33242457

Group type: EXPERIMENTAL
Intervention: Nevirapine dosed at 6 mg/kg twice daily for term neonates or 4 mg/kg twice daily for 1 week and 6 mg/kg twice daily thereafter for preterm neonates.
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Nevirapine treatment
Number of subjects: 438
Study: 33242536

Group type: EXPERIMENTAL
Intervention: Olaparib for up to 10 weeks before chemotherapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 32
Study: 33242544

Group type: EXPERIMENTAL
Intervention: ADHD, DMDD, both disorders, or no major psychopathology
Number of subjects: 187
Study: 33242662

Group type: EXPERIMENTAL
Intervention: PD patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study: 33242991

Group type: EXPERIMENTAL
Intervention: Post-traumatic headache
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Non-concussive headaches
Number of subjects: 1094
Study: 33243016

Group type: EXPERIMENTAL
Intervention: Therapeutic Education and Physical Activity (TEPA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Therapeutic Education
Number of subjects: 40
Study: 33243049

Group type: EXPERIMENTAL
Intervention: Bendamustine plus obinutuzumab (BG)
Number of subjects: 0
Study: 33243149

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric prilocaine (35 to 50 mg) co-administered with 2.5 mcg of sufentanil and 100 mcg of morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric prilocaine with sufentanil and morphine
Number of subjects: 0
Study: 33243204

Group type: EXPERIMENTAL
Intervention: Community gardening participation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (non-gardeners)
Number of subjects: 66
Study: 33243251

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombospondin 1 (TSP1) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (macular hole patients)
Number of subjects: 0
Study: 33243252

Group type: COMPARATOR
Intervention: Traditional school children during summer vacation (Condition 1 to 2)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Year-round school children during summer vacation (Condition 2 to 3)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Traditional school children (Condition 2)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Year-round school children (Condition 3)
Number of subjects: 285
Study: 33243378

Group type: EXPERIMENTAL
Intervention: BAV patients after TAVR
Number of subjects: 204

Group type: COMPARATOR
Intervention: TAV patients after TAVR
Number of subjects: 204
Study: 33243789

Group type: EXPERIMENTAL
Intervention: Long-bout sedentary behaviour (≥90 min) in patients with diabetes mellitus (DM)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Sedentary behaviour (general)
Number of subjects: 379
Study: 33243800

Group type: EXPERIMENTAL
Intervention: Lyso-Thermosensitive Liposomal Doxorubicin (LTLD) combined with Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU)
Number of subjects: 12
Study: 33243816

Group type: EXPERIMENTAL
Intervention: Individualised nurse-led education sessions
Number of subjects: 30
Study: 33244300

Group type: EXPERIMENTAL
Intervention: Rejuveinix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lipopolysaccharide-Galactosamine Mouse Model
Number of subjects: 0
Study: 33244458

Group type: EXPERIMENTAL
Intervention: Erlotinib 100 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gefitinib 250 mg/d
Number of subjects: 0
Study: 33244711

Group type: EXPERIMENTAL
Intervention: Netarsudil ophthalmic solution 0.02% (n=8)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle (n=4)
Number of subjects: 12
Study: 33244719

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery for rectal cancer
Number of subjects: 323
Study: 33245115

Group type: EXPERIMENTAL
Intervention: GBM stem-like cells (GSLCs) grown in classical 2D culture and in 3D-tumor organoids
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: GBM stem-like cells (GSLCs)
Number of subjects: 2
Study: 33245172

Group type: EXPERIMENTAL
Intervention: SCB01A, a microtubule inhibitor, administered intravenously for 3 hours once every 21 days, starting dose 2 mg/m², escalated to a maximum tolerated dose (MTD) of 24 mg/m².
Number of subjects: 0
Study: 33245179

Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 0
Study: 33246099

Group type: EXPERIMENTAL
Intervention: Standardized 6-min walk test (6MWT)
Number of subjects: 0
Study: 33246186

Group type: EXPERIMENTAL
Intervention: Common care pathways (5 identified pathways)
Number of subjects: 3133

Group type: EXPERIMENTAL
Intervention: Number of transitions (median 3, interquartile range 2-3)
Number of subjects: 3133

Group type: EXPERIMENTAL
Intervention: Demographic and injury-related factors (increased age, violence as cause of injury, pre-injury systemic disease, intracranial and overall injury severity, regions of Southern/Eastern Europe)
Number of subjects: 3133
Study: 33246388

Group type: EXPERIMENTAL
Intervention: Urban Zen Integrative Therapy (UZIT)
Number of subjects: 13
Study: 33246407

Group type: EXPERIMENTAL
Intervention: Home health care (HHC)
Number of subjects: 600
Study: 33246438

Group type: EXPERIMENTAL
Intervention: Sense of coherence (SOC)
Number of subjects: 4918

Group type: COMPARATOR
Intervention: Patients without neoplasms
Number of subjects: 4918
Study: 33246478

Group type: EXPERIMENTAL
Intervention: Ultrasound shear wave elastography (SWE) for assessing diaphragm function
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Various pressure support settings and spontaneous breathing trial (SBT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Respiratory rate comparison
Number of subjects: 30
Study: 33246496

Group type: EXPERIMENTAL
Intervention: Case study design methodology for process evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case study design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Core components of process evaluation
Number of subjects: 0
Study: 33246589

Group type: EXPERIMENTAL
Intervention: Schizophrenia (SP) group
Number of subjects: 126

Group type: COMPARATOR
Intervention: Healthy control (HC) group
Number of subjects: 126
Study: 33246973

Group type: EXPERIMENTAL
Intervention: Deoxycytidine and deoxythymidine therapy
Number of subjects: 6
Study: 33247014

Group type: EXPERIMENTAL
Intervention: Topical or systemic treatments for atopic dermatitis (AD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 33247029

Group type: EXPERIMENTAL
Intervention: Urban areas
Number of subjects: 211
Study: 33247178

Group type: EXPERIMENTAL
Intervention: STAT3 and TP53 mutations
Number of subjects: 0
Study: 33247327

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33247912

Group type: EXPERIMENTAL
Intervention: Live donor uterus transplantation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Recipient costs
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cost components
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Health care perspective
Number of subjects: 9
Study: 33248099

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33248295

Group type: EXPERIMENTAL
Intervention: Pharmacologic prophylaxis
Number of subjects: 3296

Group type: COMPARATOR
Intervention: No pharmacologic prophylaxis
Number of subjects: 3296
Study: 33248442

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Lobectomy/Ishtmusectomy (L/I)
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Total Thyroidectomy (TT)
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Change from AS to surgery due to disease progression
Number of subjects: 1055
Study: 33248473

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33248962

Group type: EXPERIMENTAL
Intervention: CMR (Cardiovascular Magnetic Resonance)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 2DE (2-dimensional echocardiography)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 2DE-GLS (2-dimensional echocardiography Global Longitudinal Strain)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tagged-CMR GLS (Cardiovascular Magnetic Resonance Global Longitudinal Strain)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: FT-GCS (Feature-Tracking Global Circumferential Strain)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CMR and 2DE-LVEF (Left Ventricular Ejection Fraction)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 2DE-GLS
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Combination of 2DE-LVEF or LVESVi and strain
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CMR left ventricular ejection fraction and FT strain
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 2DE GLS
Number of subjects: 125
Study: 33248965

Group type: EXPERIMENTAL
Intervention: Machine learning identified 6 clusters for low FFR, relevant features include minimum lumen area, percent atheroma volume, fibrofatty and necrotic core volume, plaque volume, proximal left anterior descending coronary artery lesion, and remodeling index.
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Incremental prognostic value of 6 relevant features over percent diameter stenosis and FFR.
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: 5-year vessel-oriented composite outcome risk increased with every increment of the number of 6 relevant features.
Number of subjects: 1013
Study: 33249200

Group type: EXPERIMENTAL
Intervention: ICD/cardiac resynchronization therapy - defibrillator replacement
Number of subjects: 983
Study: 33249510

Group type: EXPERIMENTAL
Intervention: Less robust 24-h rest-activity rhythms (lower relative amplitude)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Less robust rest-activity rhythms
Number of subjects: 411
Study: 33249569

Group type: EXPERIMENTAL
Intervention: Sickle cell disease patients (SS)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Healthy adult controls (AA)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Sickle cell disease patients (SS) with retinopathy
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Sickle cell disease patients (SS) with a history of priapism
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Sickle cell disease patients (SS) with leg ulcers
Number of subjects: 232
Study: 33249636

Group type: EXPERIMENTAL
Intervention: Combined treatment for 16 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 40
Study: 33249802

Group type: EXPERIMENTAL
Intervention: UST 130 mg
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: UST 6 mg/kg
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: UST 90 mg q12w
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: UST 90 mg q8w
Number of subjects: 133
Study: 33249870

Group type: EXPERIMENTAL
Intervention: Neurovascular contact with morphological changes on the symptomatic side
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Neurovascular contact with morphological changes on the asymptomatic side
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Demyelination along the intrapontine trigeminal afferents
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Microvascular decompression
Number of subjects: 63
Study: 33249901

Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 189
Study: 33249933

Group type: EXPERIMENTAL
Intervention: Intraoperative pain management techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pain management
Number of subjects: 0
Study: 33250039

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) with cutoff <26
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) with cutoff <27
Number of subjects: 521
Study: 33250131

Group type: EXPERIMENTAL
Intervention: 1L-PEG
Number of subjects: 1004

Group type: COMPARATOR
Intervention: 4L-PEG
Number of subjects: 1004
Study: 33250788

Group type: EXPERIMENTAL
Intervention: Behavioral paradigms to facilitate treatment development
Number of subjects: 0
Study: 33250848

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33251157

Group type: EXPERIMENTAL
Intervention: Griffithsin (GRFT)
Number of subjects: 0
Study: 33251516

Group type: EXPERIMENTAL
Intervention: Parenteral ascorbic acid (1,500 mg), hydrocortisone (50 mg), and thiamine (100 mg) every 6 hours for 4 days
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 33251691

Group type: EXPERIMENTAL
Intervention: Eculizumab (nine infusions during the first 2 months posttransplant)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 20
Study: 33251753

Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive behavioural therapy (Tele-CBT)
Number of subjects: 10
Study: 33251774

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment with non-flow limiting dissection
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment with flow limiting dissection
Number of subjects: 227

Group type: COMPARATOR
Intervention: Drug-coated balloon (DCB) treatment
Number of subjects: 227
Study: 33251855

Group type: EXPERIMENTAL
Intervention: Traumatic events
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Nontraumatic events
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: No events
Number of subjects: 347
Study: 33252266

Group type: EXPERIMENTAL
Intervention: secukinumab
Number of subjects: 0
Study: 33252283

Group type: EXPERIMENTAL
Intervention: Laser-assisted retrieval using a laser sheath powered by 308-nm XeCl excimer laser system (CVX-300; Spectranetics) after failed standard retrieval methods.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Laser-assisted retrieval
Number of subjects: 500
Study: 33252292

Group type: EXPERIMENTAL
Intervention: IVF treatment interrupted or postponed due to COVID-19
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Time spent on COVID-19 related news per day
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Partner with evidence of psychological disorder
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Diagnosis of poor ovarian reserve, endometriosis, or uterine fibroids (in females)
Number of subjects: 524
Study: 33252313

Group type: EXPERIMENTAL
Intervention: Postpartum plasma B vitamin and homocysteine profiles
Number of subjects: 0
Study: 33252344

Group type: EXPERIMENTAL
Intervention: Brief sleep intervention in infancy
Number of subjects: 734

Group type: COMPARATOR
Intervention: Control group (no sleep intervention)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Follow-up at age 11 years
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 734
Study: 33252347

Group type: EXPERIMENTAL
Intervention: eHealth interventions integrating PSD principles and BCTs
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Behavior Change Techniques (BCTs)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Persuasive System Design (PSD) principles
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination of BCTs and PSD principles
Number of subjects: 23
Study: 33252547

Group type: EXPERIMENTAL
Intervention: HLA-C (T and TT variants - rs10484554)
Number of subjects: 333

Group type: COMPARATOR
Intervention: ZNRD1 (T allele - rs3869068)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: ZNRD1 (CT and TT genotypes - rs3869068)
Number of subjects: 333
Study: 33252834

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: HPV16/18 E6 oncoprotein (E6)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: p16/Ki-67 dual-stained cytology (DS)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Direct referral of all HPV16/18-positive women
Number of subjects: 739
Study: 33252930

Group type: EXPERIMENTAL
Intervention: Semiautomated tracking of fluid consumption
Number of subjects: 31
Study: 33253089

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg subcutaneous (s.c.)
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg s.c. in fast progressors
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Placebo in fast progressors
Number of subjects: 1602
Study: 33253198

Group type: EXPERIMENTAL
Intervention: Asymptomatic malaria
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Clinical malaria
Number of subjects: 1118
Study: 33253641

Group type: EXPERIMENTAL
Intervention: Intravesical nadofaragene firadenovec (75 mL dose, 3×10^11 viral particles)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Intravesical nadofaragene firadenovec
Number of subjects: 157
Study: 33253692

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) based on surface multifield technology applied to the contralesional wrist and finger extensors during the turn on the light task (TOTL).
Number of subjects: 11
Study: 33253997

Group type: EXPERIMENTAL
Intervention: Cabozantinib, median average daily dose 40.0 mg, treatment duration median 7.6 months
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Cabozantinib initiation at 60 mg/day
Number of subjects: 410
Study: 33254134

Group type: EXPERIMENTAL
Intervention: Bilateral ventralis oralis posterior/ventralis intermedius (Vop/Vim) deep brain stimulation (DBS)
Number of subjects: 4